

SUSTAINED REPORTER AIRWAY GENE EXPRESSION WITH A LENTIVIRAL VECTOR IN CYSTIC FIBROSIS MICE

Patricia Cmielewski^{1,3}, Donald Anson^{2,4}, David Parsons^{1,3,4,5}

1. Respiratory and Sleep Medicine, Women's and Children's Hospital, SA
2. Gene Technology Unit, SA Pathology
3. Department of Paediatrics, University of Adelaide, SA
4. Centre for Stem Cell Research, University of Adelaide, SA
5. Women's and Children's Health Research Institute, SA

Introduction

Non-invasive bioluminescence imaging has allowed for rapid *in-vivo* quantification of long-lasting gene transfer in experimental animals. We studied the sustainability of lentiviral (LV) reporter gene transfer over the lifetimes of cystic fibrosis (CF) mice.

Methods

CF^{TR1Luc} mice received a nasal bolus of lysophosphatidylcholine (LPC) or a control (PBS) pre-treatment one hour prior to delivery of a LV vector containing the reporter gene luciferase (LV-Luc). Another control group received LPC one hour prior to an empty vector (LV-MT). Bioluminescence was measured at 1 wk & 1, 3, 6, 9, 12, 15, 18 and 21 months after LV dosing. Circulating antibodies to the Luc transgene were analysed in sera by ELISA at all time points.

Results

Nasal bioluminescence was significantly increased with LPC/LV-Luc compared to controls for 12 months (Fig. 1a, $p < 0.05$, ANOVA). There was no difference in lung luminescence between the LPC and PBS pre-treated mice that received LV-Luc (Fig. 1b). No bioluminescence was detected in the airways of mice treated with LPC/LV-MT (Fig. 2). At later time points, the low sample size due to animal attrition influenced mean expression levels. There was a significant increase in the presence of circulating antibodies to the Luc transgene in those mice that received LPC prior to LV-Luc compared to both control groups (Fig. 3, $p < 0.05$, ANOVA). Antibodies to Luc persisted from 1 month to 21 months, peaking at 3 months, following a single gene therapy dose of LPC/LV-Luc.




Fig. 1. a) Nasal and b) Lung LV-luciferase luminescence. Mean \pm SEM, * $p < 0.05$, RM ANOVA, $n = 3-12$, # n too low for analysis.




Fig. 2. LV-luciferase luminescence LV-MT (left), PBS (middle) vs LPC (right)




Fig. 3. Circulating antibodies to the transgene Luciferase. Mean \pm SEM, * $p < 0.05$, RM ANOVA, $n = 3-12$.

Conclusions

Lentiviral luciferase gene expression was significantly improved in mouse nasal airways using LPC pre-treatment. However, pre-treatment made no difference to luciferase expression in the lungs of CF mice. The presence of circulating antibodies to luciferase for longer than 18 months suggests an immune response to a sustained long term transgene expression.

Acknowledgements

NH&MRC and philanthropic donors (www.Cure4CF.org)